---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-049931"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T08:23:25.791321+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M

## Summary
- TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).
- Adjusted EBITDA estimated at $26.5M for FY2024, margin ~19.7% (high teens % of revenue).
- Net leverage ratio 1.15x; debt/equity 0.90x; $20M stock repurchase program available.
- Capital allocation prioritized: organic growth, debt reduction (target leverage 1.5x-2.0x), and opportunistic buybacks.
- Patient Services gross margin improved to 66.0% TTM; Device Solutions gross margin 31.3% TTM.

## SEC filing metadata
- accession: 0001628280-24-049931
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/0001628280-24-049931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/infu-20241204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-049931
- JSON: https://secwatch.observer/filing/0001628280-24-049931.json
- Plain text: https://secwatch.observer/filing/0001628280-24-049931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.